Why it’s on the map
Section 232 pharma tariffs (100% on patented imports from July 31, 2026). Near-total US API production shields Lilly while rivals importing from Ireland pay 15–100%. ≥$27B in four new US plants.
Government money & contracts
MFN/TrumpRx deal (Nov 2025).
Customers & commercial
Global.
Catalysts
Sept 29 Annex III implementation; Q3 late Oct.
Risk
MFN pricing compression.
Tariff durability
Section 232 (durable).
Dividend · #43 of 47 payers by yield
0.49% yield
$6.92 a share a year · quarterly · pays Mar · Jun · Sept · Dec
Per payment$1.73a share, 4× a year
Next payoutDec 10declared · $1.73 a share
Last ex-dateAug 14, 2026next ex-date Nov 13, 2026
Last paidSept 10, 2026$1.73 a share
Payout ratio22%of earnings · well covered
Raised11 yrsconsecutive years of increases
Shares at the Oct 30 close of $1,417.540.71
Each payment$1.22
Per year · 4 payments$4.88
Recent payments
| Ex-date | Paid | Per share | |
|---|---|---|---|
| Aug 14, 2026 | Sept 10, 2026 | $1.73 | |
| May 15, 2026 | Jun 10, 2026 | $1.73 | |
| Feb 13, 2026 | Mar 10, 2026 | $1.73 | |
| Nov 14, 2025 | Dec 10, 2025 | $1.50 | before the raise |
Yield = $1.73 × 4 ÷ the Oct 30 close of $1,417.54. A dividend is a board decision, not a promise — it can be raised, cut or suspended any quarter. Dividend history source